Beta Bionics Quarterly Balance Sheet
NASDAQ: BBNXHealth CareMedical/Dental InstrumentsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Beta Bionics financial position
As of Jun 30, 2026, Beta Bionics reported total assets of $292.4 million, down 11.4% from a year earlier against total liabilities of $36.0 million. Shareholders' equity stood at $256.4 million, or 87.7% of assets. The company held $44.3 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 8.88, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Beta Bionics balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 44.32M | 30.21M | 31.58M | 38.48M | 35.08M | 42.45M | 30.43M | 17.48M | 13.03M | 22.07M | 26.57M |
| Short-Term Investments | 136.17M | 169.31M | 187.55M | 190.20M | 214.65M | 189.02M | 73.14M | — | — | — | 70.18M |
| Receivables | 18.05M | 15.75M | 17.12M | 11.54M | 11.39M | 9.06M | 12.00M | — | — | — | 4.45M |
| Inventory | 23.92M | 23.73M | 21.72M | 20.37M | 17.32M | 15.73M | 13.32M | — | — | — | 1.25M |
| Total Current Assets | 231.03M | 247.99M | 267.90M | 270.03M | 286.07M | 261.92M | 132.92M | — | — | — | 103.62M |
| Property, Plant & Equipment | 10.75M | 10.16M | 8.60M | 7.38M | 6.46M | 5.51M | 4.78M | — | — | — | 2.48M |
| Long-Term Investments | 44.65M | 39.87M | 45.43M | 45.33M | 31.15M | 64.00M | — | — | — | — | — |
| Total Assets | 292.39M | 304.42M | 328.74M | 330.05M | 329.97M | 338.02M | 149.65M | — | — | — | 110.04M |
| Accounts Payable | 5.35M | 2.32M | 5.00M | 4.46M | 3.42M | 3.45M | 2.85M | — | — | — | 1.17M |
| Total Current Liabilities | 26.02M | 23.19M | 30.92M | 25.39M | 19.49M | 16.49M | 21.15M | — | — | — | 10.61M |
| Total Liabilities | 36.02M | 33.17M | 41.13M | 35.29M | 28.34M | 24.27M | 73.63M | — | — | — | 51.43M |
| Shareholders' Equity | 256.37M | 271.25M | 287.61M | 294.76M | 301.63M | 313.75M | -245.36M | -228.85M | -221.21M | -214.32M | -203.10M |
| Retained Earnings | -415.24M | -391.83M | -369.94M | -356.47M | -342.26M | -325.39M | -296.74M | — | — | — | -229.66M |
| Net Cash (Debt) | 180.49M | 199.52M | 219.13M | 228.69M | 249.72M | 231.47M | 103.58M | 17.48M | 13.03M | 22.07M | 96.75M |
| Shares Outstanding | 44.98M | 44.56M | 44.36M | 43.99M | 43.47M | 43.35M | 6.67M | — | — | — | — |
This table shows 11 quarterly periods of Beta Bionics's balance sheet, from Q2 2026 back to Q4 2023, across 15 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow BBNX's reporting calendar. What is a balance sheet?